Dr. Abida is Director of Translational Research in Prostate Cancer and Associate Member in the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. His research focuses on the genomics of prostate cancer and on the development of molecularly-guided therapies in prostate cancer and other solid tumors. He is involved in multiple prostate cancer genomic profiling efforts, including the Stand Up to Cancer International Prostate Cancer Dream Team project, and he leads analysis MSKCC’s prostate cancer genomics datasets. He also leads clinical trials investigating DNA repair and epigenetic-targeting agents in prostate cancer and other malignancies. One of these trials resulted in the first FDA approval of a PARP inhibitor, rucaparib, for the treatment of prostate cancer.

Dr. Abida obtained his M.D. and Ph.D. degrees at Columbia University and completed internal medicine residency training at the Hospital of the University of Pennsylvania. He completed his medical oncology fellowship training at Memorial Sloan Kettering Cancer Center, where he studied mechanisms of androgen receptor activity in the laboratory of Dr. Charles L. Sawyers, and served as Chief Fellow in hematology/oncology. His awards include a Department of Defense Physician Research Award and a Young Investigator Award from the Prostate Cancer Foundation. He has co-led two NCI SPORE-funded research projects.